World Health Organization Sounds Concern Over Critical Scarcity of Weight-Loss Jabs
Less than one in 10 people eligible to benefit from obesity jabs like Wegovy can access them, caution the WHO as it issues its first recommendations on the drugs.
With in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is urging more widespread and fairer access to these injectable treatments.
Based on projections, over two billion are projected to be obese by 2030 without intervention.
"The latest guidelines recognises that obesity is a chronic disease that can be managed with holistic and continuous treatment," stated WHO director-general Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and logistical bottlenecks are key barriers to universal access to the treatments that can help people shift considerable weight, notes the organization.
GLP-1 Therapy Supply Crisis
Despite the present most favorable case, the supply of GLP-1 therapies would only suffice for about 100 million people – less than 10% of those who need them, according to the WHO.
The advice encourages governments and firms to expand access, by strategies including licensing agreements.
The intellectual property rights on semaglutide – the primary ingredient of a leading brand – is scheduled to end in several countries in 2026.
The Way Obesity Injections Operate
These medications imitate a biological compound to slow digestion, curb appetite and enhance satiety so individuals reduce food intake.
Patients usually see weight reduction within a few weeks of commencing the regular doses.
Research points to users may see weight return a year later of discontinuing the drug, as their usual appetite come back.
To be above a healthy weight increases your risk for contracting health problems, including type 2 diabetes, heart disease, brain attack, and certain cancers.
Obesity impacts individuals in all nations and was linked to millions of fatalities worldwide in 2024, per the WHO.